GH Research (GHRS) Gains from Investment Securities (2021 - 2025)
GH Research's (GHRS) quarterly Gains from Investment Securities came in at $90000.0 in Q4 2025, down 49.72% year-on-year from $179000.0 in Q4 2024, and up 328.57% quarter-over-quarter from $21000.0 in Q3 2025.
GH Research (GHRS) Gains from Investment Securities (2021 - 2025) Analysis & Trends
GH Research's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $90000.0 for Q4 2025.
- On a quarterly basis, Gains from Investment Securities fell 49.72% year-over-year to $90000.0 in Q4 2025; TTM through Dec 2025 was $463000.0, a 35.43% decrease from a year earlier, with the FY2025 full-year figure at $463000.0, down 35.43% from the prior year.
- Gains from Investment Securities climbed to $90000.0 in Q4 2025 per GHRS's latest filing, from $21000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $189000.0 in Q4 2023 and bottomed at $3000.0 in Q3 2021.
- The 5-year median for Gains from Investment Securities is $178000.0 (2024), against an average of $144928.6.
- Across the five-year window, Gains from Investment Securities soared 53.66% in 2023 and plunged 88.4% in 2025, its largest moves.
- Year by year, Gains from Investment Securities stood at $3000.0 in 2021, then soared by 4000.0% to $123000.0 in 2022, then surged by 53.66% to $189000.0 in 2023, then dropped by 5.29% to $179000.0 in 2024, then plunged by 49.72% to $90000.0 in 2025.
- Per Business Quant, the three latest GHRS Gains from Investment Securities figures stand at $90000.0 (Q4 2025), $21000.0 (Q3 2025), and $174000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | GH Research | 1.70 Bn | 1.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90,000.00 |
| Dec 31, 2025 | 90,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Sep 30, 2024 | 181,000.00 |
| Sep 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Dec 31, 2023 | 189,000.00 |
| Dec 31, 2023 | 189,000.00 |
| Sep 30, 2023 | 184,000.00 |
| Sep 30, 2023 | 184,000.00 |